Proteonomix, Inc. Announces Screening of Patients with End Stage
Liver Disease in its Clinical Study of UMK-121
PARAMUS, N.J., Nov. 20,
2012 /PRNewswire/ -- PROTEONOMIX, INC. (OTCBB: PROT), a
biotechnology company (the "Company") focused on developing
therapeutics based upon the use of human cells and their
derivatives, announced today that the University of Medicine & Dentistry of New
Jersey (UMDNJ) in conjunction with the Company has commenced
the screening of patients with End Stage Liver Disease (ESLD) for
use in its clinical trial of UMK-121.
Michael Cohen, the Chief
Executive Officer of the Company stated: "At least thirty (30)
patients have been screened so far pursuant to inclusion and
exclusion criteria approved by the Institutional Review Board as
part of the protocol. The initiation of screening is the
first step towards commencement of the clinical trial of
UMK-121."
About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing
therapeutics based upon the use of human cells and their
derivatives. The Proteonomix family of companies includes
Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a
wholly owned subsidiary that has developed an anti-aging line of
skin care products. StromaCel develops therapeutic modalities for
the treatment of cardiovascular disease and for treatment of
patients who have suffered post-myocardial infarction. Proteonomix
Regenerative Translational Medicine Institute, Inc. (PRTMI) intends
to focus on the translation of promising research in stem cell
biology and cellular therapy to clinical applications of
regenerative medicine. Additional information is available at
www.proteonomix.com and www.proteoderm.com.
Forward-looking statements:
Certain statements contained herein are "forward-looking
statements" (as defined in the Private Securities Litigation Reform
Act of 1995). Proteonomix, Inc. cautions that statements made in
this press release constitute forward-looking statements and makes
no guarantee of future performance. Actual results or developments
may differ materially from projections. Forward-looking statements
are based on estimates and opinions of management at the time
statements are made.
SOURCE Proteonomix, Inc.